Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announces that its majority-owned subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp (“Denali”), a special purpose acquisition company, announced the closing of their previously announced business combination (the “Business Combination”). The combined company will operate as “Semnur Pharmaceuticals, Inc.”
Source: https://www.globenewswire.com/news-release/2025/09/22/3154269/0/en/Semnur-Pharmaceuticals-Inc-Semnur-a-Majority-Owned-Subsidiary-of-Scilex-Holding-Company-Nasdaq-SCLX-Scilex-and-Denali-Capital-Acquisition-Corp-Announce-the-Closing-of-Their-Previou.html